Investor Presentation for the Quarter ended June 30, 2026 is attached herewith

239/LG/SE/AUG/2026/GBSL August 14, 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presentation Dear Sir/Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation on Unaudited Financial Results of the Company for the quarter ended June 30, 2026. Kindly take the same on record. Thanking You, Yours truly, For Gufic Biosciences Limited Ami Shah Company Secretary & Compliance Officer Membership No. A39579 Encl.: As above Investor Presentation Delivering Care & Cure For Q1FY2027 Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosciences Limited (the “Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions. This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer or recommendation to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment thereof. In particular, this presentation is not intended to be a prospectus or offer document under the applicable laws of any jurisdiction, including India. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. There is no obligation to update, modify or amend this communication or to otherwise notify the recipient if the information, opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate. Certain statements contained in this presentation that are not statements of historical fact constitute “forward-looking statements.” You can generally identify forward looking statements by terminology such as “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “objective”, “goal”, “plan”, “potential”, “project”, “pursue”, “shall”, “should”, “will”, “would”, or other words or phrases of similar import. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or other projections. Important factors that could cause actual results, performance or achievements to differ materially include, among others: (a) our ability to successfully implement our strategy, (b) our growth and expansion plans, (c) changes in regulatory norms applicable to the Company, (d) technological changes, (e) investment income, (f) cash flow projections, and (g) other risks. This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes. Q1 FY27 Business & Financial Highlights Indore Facility update: The Manufacturing Platform Timeline of our phased approach We have built one of the most advanced lyophilized injectable facilities, commenced production in Milestone Target Status & Commentary October 2024 Installation & Operational ✅Completed –facility meets WHO GMP, EU GMP, ANVISA, October 2023 Qualification (IQ/OQ) MHRA, USFDA design standards Designed for WHO GMP, EU GMP, ANVISA, MHRA, Performance Qualification (PQ) ✅Completed with multiple container trials; parameters Dec 2023 –Jun 2024 and USFDA standards, it houses: All Lines & Utilities locked  Lyophilized vials – 5 million/month Media Fills Jul 2024 –Oct 2024 ✅Completed for all four lines; sterility validated  Liquid vials – 6 million/month (Aseptic Process Simulations)  Ampoules – 10 million/month Product Permissions from State FDA Ongoing 🟡 203 approvals received to date; more in pipeline The qualification phase is behind the site. Q1 work Tech Transfer for existing products 🟡 Completed for 40 products; moved to capability extension — the depot and from Navsari & Process Validation Oct 2024 –ongoing stability studies in progress. 27 more products under Batches for initial products development microsphere suite is at the verge of completion, enabling manufacture of long-acting depot Vendor Audits 🟡 20+ completed, more lined up; CMO contracts H1-FY26 Indian Pharma Majors commenced presentations 30% Capacity Utilization FY26 🟡 On-track Set-up commenced for a spray-dried route to a lipid- based antifungal, alongside qualification of a Global Regulatory Clearance conventional route for the same format. These are formats very few Indian sites operate; both are EU GMP & UK MHRA FY27 🟡 EU audit completed; certification awaited targeted to become operational during the year. 🔵Filed with US authorities on behalf of a client to trigger US FDA FY29 inspection; Gufic participates as a pure-play CDMO partner Direction: Scale-up is deliberately paced. The site’s cost base is already in the reported numbers; the operating leverage it was built to create sits behind the certifications now in progress. Indore Plant: The Journey So Far Gufic Advantage What We Delivered Quarter by Quarter Fully Integrated Injectable Platform Quarter Milestone Detail / Evidence Barrier Why It Matters Q4 FY25 Commercial production Oct 2024 first batch; plant capitalized Q3 FY25 One of the largest Indian companies that can manufacture (Capitalized) commenced Lyophilisation at scale lyophilized injectables at scale. Navsari saturated; all incremental growth = Q1 FY26 Indore. High volume molecules shifted in phase First revenue contribution Lyophilized + Liquid Vials + Ampoules + Microspheres + NDDS (DCB, (Apr-Jun '25) 1. 145 State FDA approvals. 9 Lyo + 3 Liquid + 3 Multi-format complexity DCS) + Depot —very few companies can run this breadth under one Ampoule tech transfers done; 8 in progress roof 40 tech transfers Q2 FY26 Product mix shifted to volume products. 18 CMO completed; 27 under (Jul-Sep '25) vendor audits completed. development WHO GMP + EU GMP + UK MHRA + ANVISA + TGA + Health Canada + Regulatory multi-accreditation Russian GMP + Oman GMP + Iraq GMP + UAE GMP —10+ (Indore + Navsari) 203 State FDA approvals received. 20+ vendor concurrent accreditations = moat against new entrants Q3 FY26 On track for 30% capacity audits. EU competent authority audit completed (Oct-Dec '25) utilization first week December 2025. Indore batch sizes (100K+ vials/batch) vs Industry avg(40K) = 2.5x Scale up of phase 1 GLP-1 validation batches (for big pharma client) Batch size economics unit economics for export (QP release cost fixed per batch, not per Q4 FY26 molecules commenced in executed in Jan 26. CMO client migration vial) (Jan-Mar '26) CMO; regulatory audit underway from Navsari Unit-2 to Indore focus Depot and microsphere suite nearing 20+ Indian pharma majors have audited or are CMO partners —this Q1 FY27 Capability extension and completion; spray-dried and conventional routes CDMO credibility is the ultimate third-party quality validation (Apr-Jun '26) regulatory sequencing for a lipid-based antifungal under set-up; contract-client migration continuing I. Hospital Injectable Platform. Therapy Focus: Anti-Microbials, Immunology & Cardiac Critical Care A. Critical Care Cluster B. Sparsh Hospital-first [Showing first 8,000 characters — download PDF for full document]